<?xml version="1.0" encoding="UTF-8"?>
<p id="Par58">In severe cases of secondary HLH/MAS, anti-IFN-γ treatment is a critical therapeutic option. There is also an ongoing trial of omapalumab (anti-IFN-γ monoclonal antibody) and anakinra in COVID-19 (NCT04324021).</p>
